Molecular structure of IKK-2 Inhibitor IV, CAS Number: 507475-17-4
IKK-2 Inhibitor IV (CAS 507475-17-4)
See product citations (12)
Alternate Names:
TPCA-1
Application:
IKK-2 Inhibitor IV is a potent inhibitor of IKKβ (IKK-2)
CAS Number:
507475-17-4
Purity:
>95%
Molecular Weight:
279.30
Molecular Formula:
C12H10FN3O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
IKK-2 inhibitor IV is a potent inhibitor of IKKbeta (IKK-2) which interferes with NF-kappaB DNA binding and therefore expression of many inflammatory genes. It inhibits lipopolysaccharide-induced human monocyte production of TNF-alpha and decreases the severity of murine collagen-induced arthritis. IKK-2 Inhibitor IV may act to reduce Endothelin-1 stimulated Monocyte Chemotactic Protein-1 production in human airway smooth muscle cells. It also inhibits up-regulation of bradykinin B1 and B2 receptor-mediated contractions. IKK-2 Inhibitor IV is an inhibitor of IKKalpha.
IKK-2 Inhibitor IV (CAS 507475-17-4) References
- Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. | Podolin, PL., et al. 2005. J Pharmacol Exp Ther. 312: 373-81. PMID: 15316093
- Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. | Birrell, MA., et al. 2005. Am J Respir Crit Care Med. 172: 962-71. PMID: 16002568
- IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. | Birrell, MA., et al. 2006. Mol Pharmacol. 69: 1791-800. PMID: 16517756
- Inhibition of Abeta production by NF-kappaB inhibitors. | Paris, D., et al. 2007. Neurosci Lett. 415: 11-6. PMID: 17223266
- IL-4-stimulated NF-kappaB activity is required for Stat6 DNA binding. | Thieu, VT., et al. 2007. J Leukoc Biol. 82: 370-9. PMID: 17513694
- Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. | Kondo, Y., et al. 2008. Invest Ophthalmol Vis Sci. 49: 4850-7. PMID: 18676628
- Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1. | Sutcliffe, AM., et al. 2009. Br J Pharmacol. 157: 436-50. PMID: 19371341
- Up-regulation of bradykinin receptors in rat bronchi via I kappa B kinase-mediated inflammatory signaling pathway. | Lei, Y., et al. 2010. Eur J Pharmacol. 634: 149-61. PMID: 20184874
- Autocrine TNF-α-mediated NF-κB activation is a determinant for evasion of CD40-induced cytotoxicity in cancer cells. | Li, D., et al. 2013. Biochem Biophys Res Commun. 436: 467-72. PMID: 23751348
- Anti-melanoma activity of Cynanchi atrati Radix is mediated by regulation of NF-kappa B activity and pro-apoptotic proteins. | Son, SW., et al. 2014. J Ethnopharmacol. 153: 250-7. PMID: 24583240
- Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. | Cataldi, M., et al. 2015. Virology. 485: 340-54. PMID: 26331681
- Cytokine induced 3-D organotypic psoriasis skin model demonstrates distinct roles for NF-κB and JAK pathways in disease pathophysiology. | Todorović, V., et al. 2022. Exp Dermatol. 31: 1036-1047. PMID: 35213752
- A Role for p65 Signaling in Muscle-derived Stem Cell Survival and Differentiation | Proto, J., Lu, A., Robbins, P., & Huard, J. 2010. The FASEB Journal. 24: lb406-lb406.
Inhibitor of:
2010002M12Rik, ADAMTS-17, ADAMTS-6, AFAP-110, ANKRD29, ANKRD44, APRIL-TWEAK, ASB-18, BATF2, C1orf175, C1orf177, C1orf92, C7orf52, CARD 12, CARD 14, CARD14, CINC-1, DRIM, EG330305, EG330513, EG434219, EG624439, EG624584, EG626740, EG626970, FAIM, FAM75A3, FLJ37396, GCP-2, GIPC, HEATR3, Helios, HHV-4 LMP-1, HRF, IκB-β, IκB-δ, IκB-γ, IκB-ζ, ICAM-2, ICEBERG, IFI-202, IFIX, IK, IKK alpha, IKK beta, IKK-i, IKKα, IKKγ, IL-1δ, IL-15, IL-1RAcP, IL-26, IL-6Rα, LOC342541, LOC645941, LOC727972, LSP1, LURAP1L, LYSMD4, MD-1, MIST1, Mystique, nemo I, NFκB p50, NFKBIL2, NKRF, NLR family CARD domain-containing (NLRC), Nlrp12, OTTMUSG00000011262, OTTMUSG00000011265, OTTMUSG00000011339, OTTMUSG00000011350, P-cadherin, p105, p8, Pellino 1, PPIL5, PTAR1, RAG-1, RELL1, RELT, RESP18, RSAD2, SIMPL, SPATA2, ST2, STAF42, TALL-1, TICAM-1, TRAF2, TRAFD1, TREM-2a, TRIM30A, TRUNDD, TTC4, TTP, UNQ6126, V1RG3, ZNF682, ZNF701, ZNF705D, ZNF708, and ZNF878.Activator of:
CARD 6, Cytokeratin 19, HIVEP1, hIws1, HSV-1 ICP0, IκB-α, IκB-γ, IκB-pp40, IFN-α21, IL-13, IRAK-1, IRAK-M, Oas1e, RelB, RNF175, SHARPIN, TNFα-IP 2, TRAF7, TRIM7, UXT, and WDR61.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IKK-2 Inhibitor IV, 500 µg | sc-203083 | 500 µg | $133.00 |